Strategy
REDUCTION OF HEALTH COSTS
Swiss government chooses the wrong medicine with reference price system for drugs
Since autumn the first package of costcutting measures in Switzerlands healthcare system is being reviewed One of the measures is the socalled reference price system for pharmaceutical whose patents have expired The Government Health Department has given two models to the consultation
MEDICAL MARKETING SUPERHEROES
Imagine you could genetically engineer your medical marketing team. You can
Allow yourself a moment to dream Imagine that you could give your medical marketing team superpowers What would they be Being invisible would allow your marketers to watch competitors as they work Being able to read the minds of key opinion leaders would make your medical affairs team incredibly insightful Time travelling market access teams could...
ETHICAL BUSINESS STIMULATES BEST VALUE IN HEALTH ECONOMY
Seventy years ago average life expectancy globally was today it is Seventy years ago million people worldwide were infected with smallpox today none The disease is eradicated Thanks to initiatives such as Gavi the Vaccine Alliance more than per cent of children now get early immunisation
WAYS TO CREATE MORE AND MORE CONSISTENT PERFORMERS
In ethically promoting Pharma business field force are the resources who generate prescriptions for the products being promoted thus bring in revenue therefore the figures at the top of the line always depend upon their contribution However not all members of the field force are consistently hitting the numbers If we enable most of the field force...
AN ASIA PACIFIC CRO MARKET ANALYSIS
STEPPING INTO THE FUTURES
The increasing cost of research in the west the ongoing tightening of regulations and pricing policies and major funding cuts for biomedical research have led to an increased interest in the outsourcing of clinical trials Not only is the APAC pharma market growing faster than the rest of the world it has a large treatment nave population and has sh...
Why Quality Standards of Drugs has to be the Primary Focus Area for Pharmaceutical Industry
Perhaps not as rampantly in the developed countries but definitely in the developing countries and especially in India access to medicines comes first even earlier than the access to healthcare facilities or doctors This essentially means that come illness most likely one would swallow a pill first and then visit a doctor if at all deemed neces...
REGULATORY REFORM
How China is investing in its pharmaceutical market
Recent legislation has forced the Chinese regulatory environment to evolve establishing a friendlier environment for pharmaceutical development These changes may opendoors for pharmaceutical companies but they also create the need to adapt to the fastchanging regulatory requirements and the uncertainty that comes with legislative change The...
Advancing Production Capabilities to Boost China’s Pharmaceutical Market
The path forward is paved with Industry 4.0 and brand security solutions alongside regulatory change and new infrastructure
China is the second largest pharmaceutical market in the world according to a Top Markets Report on the countrys pharmaceutical industry by the International Trade Administration The same report also forecast the country to grow from US billion in to US billion by However despite the markets sheer size several hurdles line the path in moving
Integrated Drug Development Strategy
The nexus to value-based pricing
The burgeoning costs of healthcare globally are not sustainable The Tufts Center for the Study of Drug Development reports that it costs on average US million and years to develop and obtain regulatory approval for a new drug Driving up drug prices is the fact that only per cent of drug candidates entering clinical trials result in an approved dr...
Statin Drug Interactions and Related Adverse Reactions
Statins are a wellestablished class of drugs for the treatment of hypercholesterolemia with a proven longterm safety profile Statins have been shown to reduce the risk of cardiovascular morbidity and mortality in patients with or at risk for coronary heart disease Catapano et al Statin use is expanding and approximately per cent of the world popu...
